Pharmacyte Biotech, INC Form 4 insider transactions

Wayne Remell Walker, a Director of PharmaCyte Biotech, Inc., reported multiple transactions in common stock on March 31, 2026.

Michael M Abecassis, a Director of PharmaCyte Biotech, Inc., reported multiple transactions in common stock on March 31, 2026.

Jonathan Schechter, a Director of PharmaCyte Biotech, Inc., reported multiple transactions in common stock on March 31, 2026.

Robert Weinstein, a Director of PharmaCyte Biotech, Inc., reported multiple transactions in common stock on March 31, 2026.

PharmaCyte Biotech Director Robert Weinstein acquired 119,170 stock options with an exercise price of $0.67, vesting on the next annual meeting date.

PharmaCyte Biotech, Inc. director Wayne Remell Walker reports the acquisition of stock options.

PharmaCyte Biotech Director Jonathan Schechter acquired stock options for 119,170 shares at an exercise price of $0.67.

PharmaCyte Biotech, Inc. director Michael M. Abecassis has executed a Power of Attorney, authorizing legal representatives to manage Section 16 filings.

PharmaCyte Biotech's CEO and President, Joshua Silverman, increased his direct beneficial ownership of common stock by 100,000 shares through open market purchases totaling approximately $80,000 in early January 2026.

PharmaCyte Biotech Director Jonathan Schechter acquired 60,000 shares of common stock over three days in early January 2026.

PharmaCyte Biotech Director Robert Weinstein reported the acquisition of common stock and stock options, alongside a tax-related disposal of shares.

PharmaCyte Biotech Director Wayne Walker reported acquiring common stock and stock options, alongside a tax-related disposition of shares.

PharmaCyte Biotech's CEO and President, Joshua Silverman, reported the acquisition of 575,000 shares and the disposition of 258,750 shares for tax purposes.

PharmaCyte Biotech Director Jonathan L. Schechter reported the acquisition of common stock and stock options, alongside shares withheld for tax purposes, with one transaction noted as a late filing.

PharmaCyte Biotech Director Michael M. Abecassis reported the acquisition of common stock and stock options, alongside shares withheld for tax liability.

PharmaCyte Biotech, a 10% owner of Q/C Technologies, reported buying 889,865 Series H preferred shares and 889,865 warrants that became convertible/exercisable after shareholder approval on November 14, 2025.

Director Robert Weinstein acquired 38,009 stock options in PharmaCyte Biotech on April 30, 2024, vesting upon the next annual meeting of stockholders.

Director Wayne Walker acquired 38,009 stock options in PharmaCyte Biotech on April 30, 2024, vesting upon the next annual meeting of stockholders.

Jonathan Schechter, a director at PharmaCyte Biotech, acquired stock options for 38,009 shares at an exercise price of $2.12 on April 30, 2024.

Michael M. Abecassis, a director of PharmaCyte Biotech, Inc., acquired stock options on April 30, 2024.